Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 4(56), p. 2146-2149, 2012

DOI: 10.1128/aac.05566-11

Links

Tools

Export citation

Search in Google Scholar

Tolerability and Safety of Primaquine in Papua New Guinean Children 1 to 10 Years of Age

Journal article published in 2012 by Inoni Beteula, Inoni Betuela, Quique Bassat, Benson Kiniboro, Leanne J. Robinson, Anna Rosanas-Urgell, Danielle Stanisic ORCID, Peter M. Siba, Pedro L. Alonso, Ivo Mueller
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT Primaquine is currently the only drug available for radical cure of Plasmodium vivax and P. ovale liver infection stages, but limited safety data exist for children <10 years of age. Detailed daily assessments of side effects in glucose-6-phosphate dehydrogenase (G6PD)-normal children treated with 14 days of primaquine plus chloroquine (3 days; n = 252) or artesunate (7 days; n = 141) (0.5 mg/kg of body weight) showed that both treatments are well tolerated, do not lead to reductions in hemoglobin levels, and can thus safely be used in children 1 to 10 years of age.